checkAd

    DGAP-News  484  0 Kommentare Biotest AG: Biotest opens new plasma collection centre in Vermillion, South Dakota, USA

    DGAP-News: Biotest AG / Key word(s): Miscellaneous
    Biotest AG: Biotest opens new plasma collection centre in Vermillion, South
    Dakota, USA

    28.09.2016 / 09:16
    The issuer is solely responsible for the content of this announcement.

    ---------------------------------------------------------------------------

    /

    PRESS RELEASE

    Biotest opens new plasma collection centre in Vermillion, South Dakota, USA

    - 13 plasma collection centres in Europe

    - 21 in the US to ensure long-term plasma supply


    Dreieich, 28 September 2016. Biotest Pharmaceuticals Corporation (BPC),
    Boca Raton, USA, a 100% subsidiary of Biotest AG, Germany, a leading
    manufacturer of plasma proteins and biological products, is pleased to
    announce the addition of its newest plasma collection centre located at
    Vermillion, South Dakota, USA. The state-of-the-art facility officially
    opened its doors for business on September 26, 2016 and brings the total
    number of BPC's plasma collection centres to 21.

    "The opening of our 21st centre further reinforces our continued commitment
    to the expansion of our existing network of plasma collection centres. We
    are fully dedicated to better serve the thousands of patients worldwide who
    rely on plasma- based therapies", said Ileana Carlisle, BPC's Chief
    Executive Officer.

    BPC has invested approximately EUR1.6 million in the construction of this
    facility. The company expects to add over 40 jobs to the Vermillion local
    economy and currently has employment opportunities available for medical
    personnel.

    About human blood plasma
    Human blood plasma is a raw material used to produce plasma derived
    products, which are used to treat various illnesses of the immune system,
    the blood system, as well as in emergency medicine. Biotest is one of the
    world's six largest manufacturers of plasma protein products.

    About Biotest
    Biotest is a provider of plasma proteins and biological drugs. With a value
    added chain that extends from pre-clinical and clinical development to
    worldwide sales, Biotest has specialised primarily in the areas of clinical
    immunology, haematology and intensive medicine. Biotest develops and
    markets immunoglobulins, coagulation factors and albumins based on human
    blood plasma. These are used for diseases of the immune and haematopoietic
    systems. In addition Biotest develops monoclonal antibodies in the
    indications of cancer of plasma cells and systemic lupus erythematosus
    which are produced by recombinant technologies. Biotest has more than 2,400
    employees worldwide. The preference shares of Biotest AG are listed in the
    SDAX on the Frankfurt stock exchange.

    IR contact
    Dr. Monika Buttkereit
    phone: +49-6103-801-4406
    email: investor_relations@biotest.de

    PR contact
    Dirk Neumüller
    phone: +49-6103-801-269
    email: pr@biotest.de

    Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany www.biotest.de

    Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
    Preference shares: securities' ID No. 522723; ISIN DE0005227235
    Listing: Prime Standard
    Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
    Munich, Stuttgart

    Disclaimer
    This document contains forward-looking statements on overall economic
    development as well as on the business, earnings, financial and assets
    position of Biotest AG and its subsidiaries. These statements are based on
    current plans, estimates, forecasts and expectations of the company and are
    thus subject to risks and elements of uncertainty that could result in
    significant deviation of actual developments from expected developments.
    The forward-looking statements are only valid at the time of publication.
    Biotest does not intend to update the forward-looking statements and
    assumes no obligation to do so.


    ---------------------------------------------------------------------------

    28.09.2016 Dissemination of a Corporate News, transmitted by DGAP - a
    service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements,
    Financial/Corporate News and Press Releases.
    Archive at www.dgap.de

    ---------------------------------------------------------------------------

    Language: English
    Company: Biotest AG
    Landsteinerstraße 5
    63303 Dreieich
    Germany
    Phone: 0 61 03 - 8 01-0
    Fax: 0 61 03 - 8 01-150
    E-mail: investor_relations@biotest.de
    Internet: http://www.biotest.de
    ISIN: DE0005227235, DE0005227201
    WKN: 522723, 522720
    Indices: SDAX
    Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
    Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
    Munich, Stuttgart, Tradegate Exchange


    End of News DGAP News Service
    ---------------------------------------------------------------------------

    505879 28.09.2016


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News Biotest AG: Biotest opens new plasma collection centre in Vermillion, South Dakota, USA DGAP-News: Biotest AG / Key word(s): Miscellaneous Biotest AG: Biotest opens new plasma collection centre in Vermillion, South Dakota, USA 28.09.2016 / 09:16 The issuer is solely responsible for the content of this announcement. …

    Schreibe Deinen Kommentar

    Disclaimer